Determination of Paroxetine in Pharmaceutical Preparations Using HPLC with Electrochemical Detection

Nitasha Agrawal¹, Josep Esteve-Romero², Neeti Prakash Dubey³, Abhilasha Durgbanshi⁴, Devasish Bose¹, J. Peris-Vicente² and S. Carda-Broch*,²

¹Department of Criminology and Forensic Sciences, Dr. H.S. Gour University, Sagar, India
²Àrea de Química Analítica, Universitat Jaume I, 12080, Castelló, Spain
³Regional Forensic Science Laboratory, Dharmshala, Himachal Pradesh, India
⁴Department of Applied Chemistry, Institute of Technology, Banaras Hindu University, Varanasi, India

Abstract: A reliable and sensitive high performance liquid chromatographic method for the determination of widely prescribed antidepressant has been developed. Paroxetine is a potent selective serotonin reuptake inhibitor used for the treatment of depression and various mood disorders. The optimum mobile phase was prepared using a combination of 40% acetonitrile and phosphate buffer 0.01 M to pH 3 and running under isocratic mode at a flow rate of 1.0 ml/min. with electrochemical detection at 0.9V. The applicability of the developed method is in the field of quality control as well as for monitoring the level of drug at various concentrations during synthesis of the parent drug. The suggested methodology was validated following the guidelines of the FDA in terms of: sensitivity (LOD and LOQ, 0.005 and 0.01 ng/mL, respectively), linearity between 0.5 - 50 ng/mL (r² > 0.9999), inter- and intraday precision (< 0.259% and < 0.538%), robustness (less than 5.0%) and recovery (99.7 - 100.7%). The developed method is specific, rapid (less than 10 min), precise, reliable, accurate, cheap and suitable for routine analysis for the determination of paroxetine in pharmaceutical preparations.

Keywords: Paroxetine, HPLC, electrochemical detection, pharmaceutical.

1. INTRODUCTION

In the last few years prescription of antidepressants has increased many folds. The increase in the number of patients suffering with depression has indeed elevated the sale of antidepressants. The new drugs that enhance serotoninergic neurotransmission by potent and selective inhibition of serotonin are highest amongst the prescribed antidepressants, they are known as selective serotonin re-uptake inhibitors (SSRIs) [1]. Paroxetine, (-)-trans-4-(4-fluorophenyl)-3-(3, 4-methylenedioxy-phenoxymethyl) piperidine, is one of the SSRIs used widely as an antidepressant drug alone, or in combination, with other drugs [2]. Paroxetine is comparable to the tricyclic antidepressants in their clinical efficacy, however, it is safer and has greater acceptance by the patients. Paroxetine is devoid of sedative effect and remarkably safe in overdose also. It takes 5.2 hours to reach the peak plasma level, with extended half life (21 hours) that allowed the introduction of formulations for once daily dosing. These combined qualities made paroxetine the most widely prescribed antidepressants [3]. It is normally used in the treatment of clinical depression, obsessive-compulsive disorder, and panic disorder [4]. In a survey performed by National Drug Code Health (Atlanta, GA, USA) in 2002, paroxetine was one of the top 200 prescriptions for 2002 by number of U.S. prescriptions dispensed.

The increase in the demand of the antidepressant drug has unfortunately invited supply of fake or counterfeit drugs in the local markets just to fulfill the requirement and maintain the low cost production which in turn can be very harmful for the patients consuming these drugs unknowingly. In many developing and under developed countries, there are no proper govern on quality of the drugs supplied in the market under non-certified trade names which are readily available at the pharmacists shop and other medical stores.

During the literature survey it was also found that along with its benefits in treatment of depression, paroxetine do possess some serious health risks. Patients with depression are at a high risk of suicide attempts [5]. The European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) also issued a warning regarding prescription of paroxetine to children and also asked to closely monitor adult patients showing suicidal tendency and/or suicidal thoughts. Paroxetine is also related with withdrawal symptoms and that is why it is recommended to gradually reduce the dose over several weeks or months if decision of withdrawal is made [6]. A survey carried out by Food and Drug Administration in 2004 on children prescribed with paroxetine showed 2.7-fold raise in suicide behavior and ideation as compared to placebo. The
trend for increased suicidality was observed in both trials for depression and for anxiety disorders [7].

Paroxetine and its metabolites in human plasma, human serum, and in pharmaceutical preparations have been quantified either by high-performance liquid chromatography (HPLC) or by gas chromatography. Several methods have been developed for the determination of paroxetine in plasma, including HPLC with ultraviolet [5, 6], fluorescence (without or with derivatization using dansylchloride) [7-9], mass spectroscopy (MS) [10, 11], diode array detection [12,13], or gas chromatography with MS detection [14,15] and applied therapeutic drug level monitoring. Only few methods have been published for the simultaneous determination of paroxetine and its metabolites in plasma, using HPLC with UV [2,16]; or applied to pharmacokinetic, therapeutic drug level monitoring, toxicological screening or forensic cases [17].

The purpose of this work is to develop a rapid, simple, cost effective and selective HPLC procedure for the screening of paroxetine in pharmaceutical preparations, which is one of the most popular antidepressant widely prescribed for the treatment of depression and related mood disorders, using C18 column and electrochemical detection. The suggested method must be validated following FDA indications in terms of selectivity, sensitivity, linearity, repeatability, reproducibility, robustness and recovery [18].

2. EXPERIMENTAL

2.1. Materials

Standard of paroxetine (purity > 99.99%) was kindly gifted from Zydus Health care, Sikkim, India. Other pharmaceutical samples (Depox, Pari-GR, Parotin, Pexep, Raxit, etc) were procured from the pharmacists of local market at Sagar, India. Some of them were gifted by medical practitioners. Paroxetine-STADA was procured from pharmacist in Castellon, Spain. HPLC grade acetonitrile and methanol were purchased from Scharlau, Barcelona. Sodium dihydrogenphosphate monohydrate, potassium chloride, and HCl were from Panreac, Barcelona. NaOH was from Scharlab, Barcelona (all were > 99% purity). Ultrapure water used was prepared by using Millipore throughout the study.

2.2. Instrumentation

An Agilent Technologies chromatograph (Model HP1100, Palo Alto, CA, USA), equipped with a quaternary pump, an autosampler, a UV-Vis and electrochemical (Model HP 1049A) detectors was used. Monitoring was carried out at 230 nm with UV detector, and 0.9 V with electrochemical detector using Ag/AgCl electrode as a reference electrode and glassy carbon as the working electrode. A Shimadzu double beam UV-Vis. Spectrophotometer UV-210 system shimadzu corporation (Kyoto, Japan) was used to measure the spectra. Another chromatographic system i.e. Shimadzu Prominence HPLC, Shimadzu Corporation, equipped with an isocratic pump LC-20 AT prominence pump, an autosampler SIL-20AC and a diode array detector SPD-M20A (190-800 nm) was used. The flowrate was 1.0ml/min and the injection volume of autosampler was set at 20μl. A Kromasil C18 column (5μm particle size, 120mm × 4.6mm i.d.) Scharlab, was employed for the analytical separation. The chromatographic data was acquired by means of personal computer connected to the chromatograph by means of Shimadzu LC workstation “LC solution software”, version1.22SP1 and “HP Chemstation” for Agilent HPLC.

The pH of the mobile phase was measured with a Crison pH meter (Model micro pH 2001, Barcelona), equipped with a combined Ag/AgCl/glass electrode Crison GLP 22, Barcelona.

2.3. Standard and Pharmaceutical Sample Preparation

The commercially available tablets of paroxetine were weighed and powdered using pastel mortars. A portion of the powder equivalent to about 10 mg/ml was weighed accurately, transferred to a 100 mL calibrated flask and suspended in methanol for analysis. The samples were filtered through a 0.45μm nylon membrane filter, and then further diluted before injection.

2.4. Mobile Phase Preparation

For mobile phase preparation, various combinations of methanol:water and acetonitrile:water were prepared buffered to pH 7, pH 5 or pH 3 using 0.01 NaH2PO4 buffer salt, 0.001M KCl and adjusting the pH using NaOH or HCl. The results obtained showed better response in acetonitrile:water combinations, buffered to pH 3. All solvents were filtered through a 0.45μm filter paper and degassed.

3. RESULT AND DISCUSSION

3.1. Development and Optimization of the HPLC Method

The dissociation constant (pKa) for paroxetine is 9.9 (Table 1) which suggests that it is a non-protonated compound and falls beyond the working pH range of column (3 - 7), still to check the effect of pH paroxetine was injected using the three selected pH i.e. (3; 5 and 7), no change was observed in retention time but on the basis of other chromatographic parameters i.e. efficiency (N) and asymmetry (B/A), pH 3 was selected for the further study. The partition coefficient (log P (o/w)) of paroxetine is 3.95; suggesting that the compound is highly hydrophobic in nature. Based on that, various mobile phase combinations such as methanol: water and acetonitrile: water at different concentrations was used (Table 2). The results obtained using combination of acetonitrile:water gave better chromatographic parameters i.e. peak shape (more Gaussian), asymmetry (close to 1.000), efficiency (higher) and retention time (lower, but > 2.00 min). So for further analysis combination of acetonitrile: water (40:60) buffered to pH 3 was selected (Fig. 1). Under these conditions, paroxetine was eluted in less then 10 min, lower than the time obtained in previous works [6,7,17].

3.2. Study of Oxidation Potential

Paroxetine is the only drug amongst SSRIs which is electrochemically active. The benefit of such kind of compound is that the interference from similar group is nullified, which assures the selectivity of the method. Then the methodology show higher specificity than previous works based on HPLC coupled to UV-Visible [5,6,15,17], fluorescence [7,9,12,16] or MS detectors [10,11].
Determination of Paroxetine in Pharmaceutical Preparations

The Open Analytical Chemistry Journal, 2013, Volume 7

Fig. (1). Standard chromatogram of a standard solution of 10 ng/mL of paroxetine using the optimum mobile phase comprising acetonitrile: water (40:60) at pH 3, with electrochemical detection at 0.9 V.

Table 1. Structure and Physical Properties of Paroxetine

<table>
<thead>
<tr>
<th>Structure Dissociation Constant</th>
<th>Partition Coefficient</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="structure.png" alt="Chemical Structure" /></td>
<td>9.9</td>
</tr>
</tbody>
</table>

Table 2. Retention Behavior of Paroxetine Using Various Combination of Methanol, Acetonitrile and Water Used as Mobile Phase

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Mobile Phase</th>
<th>Ratio</th>
<th>Retention Time (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>MeOH: H2O</td>
<td>75:25</td>
<td>10.42</td>
</tr>
<tr>
<td>3.</td>
<td>MeOH: H2O</td>
<td>100:0</td>
<td>7.6</td>
</tr>
<tr>
<td>4.</td>
<td>MeOH: H2O</td>
<td>50:50</td>
<td>7.1</td>
</tr>
<tr>
<td>5.</td>
<td>MeOH: H2O</td>
<td>80:20</td>
<td>-</td>
</tr>
<tr>
<td>6.</td>
<td>Acetonitrile: H2O</td>
<td>30:70</td>
<td>14.9</td>
</tr>
<tr>
<td>7.</td>
<td>Acetonitrile: H2O</td>
<td>40:60</td>
<td>6.6</td>
</tr>
<tr>
<td>8.</td>
<td>Acetonitrile: H2O</td>
<td>45:55</td>
<td>5.2</td>
</tr>
<tr>
<td>9.</td>
<td>Acetonitrile: H2O</td>
<td>50:50</td>
<td>3.2</td>
</tr>
<tr>
<td>10.</td>
<td>Acetonitrile: H2O</td>
<td>60:40</td>
<td>2.8</td>
</tr>
</tbody>
</table>

In order to select the optimum oxidation potential for paroxetine, hydrodynamic voltammogram was plotted (Fig. 2). The potential applied varies between +0.1 to +0.9 V, in 0.1 V steps up to 0.6 V and then after at an interval of 0.05 V. By observing the results obtained for paroxetine it was concluded that paroxetine starts oxidizing above 0.5 V and reaches the maximum at 0.9 V following which a reduction is observed. Therefore on the basis of results obtained 0.9 V was selected as the potential for further study.

Fig. (2). Oxidation curve for paroxetine

3.3. Linearity and Limit of Detection

Calibration curves were constructed for paroxetine using the areas of the chromatographic peaks observed at eight increasing concentrations, each calibration level was analyzed 6 times. The concentrations were in the range 0.5-50 ng/ml using electrochemical detection, while 50-500 ng/ml for UV. The calibration parameters (slopes and intercepts) using electrochemical detection were higher than those obtained with UV detection, and then electrochemical detection was selected for the analysis of paroxetine. The regression curve was:

\[ A = (572 \pm 2) \text{[paroxetine (ng/mL)]} + (2.3 \pm 0.1) r^2 > 0.9999 \]

The limit of detection (LOD) and quantification (LOQ) for the drug were determined with the 3s and 10s criterion respectively, using a series of 10 solutions (10 to 0.01 ng/ml) containing low concentrations of the drug to calculate s. The results were based not only on the standard deviation of the response, but also on the slope of the calibration curve. LOD (0.005 ng/ml) and LOQ (0.01 ng/ml) indicate that the procedure is sensitive enough for the routine pharmaceutical and biological analysis. Sensitivity and linearity were higher than obtained in previously published works [5, 6,7,9,10,12,15-17].

3.4. Repeatability and Intermediate Precision

Repeatability was evaluated by analyzing five replicates of three standard solutions in increasing concentrations (1; 2.5 and 5 ng/mL), and reproducibility was evaluated using the same standard solutions five different days over a period of two months. The precision was determined as the CV (%) of the results. Intraday precision was: 0.259; 0.144 and 0.119% (respectively), whereas interday precision was:
0.538; 0.225 and 0.135% (respectively). The low variability and high precision of the results obtained in different days are evident, which indicate the usefulness of the method. The method was more precise than in other previously published papers [5,6,7,9,10,11,12,15-17].

3.5. Robustness

The developed method was found to be robust based on the fact that the small deliberate changes in the conditions did not have any significant effect on the chromatographic behavior of the analyte. The chromatographic conditions such as concentration of mobile phase and value of pH were slightly altered. The effects of slight changes in applied detection potential and flow-rate were also studied. Variation of the flow rate had stronger influence on the retention of the studied compounds than other selected parameters. However, the variations in all the parameters (R.S.D.) had no significant effect on retention time (< 3.5%), efficiency (< 0.4%) and asymmetry (< 6.8%). The results obtained are summarized in Table 3.

3.6. Analysis of Paroxetine in Pharmaceutical Preparations

The contents of some pharmaceutical formulations commercially available in India and Spain were determined using the developed method. Paroxetine in India and Spain sold under various trade names gave the result similar to that mentioned on the wrapper. All the available drugs were diluted to inject in the chromatographic system an amount of analyte into the linear range. In the obtained chromatograms, the paroxetine was eluted without interferences from other substances of the matrix, then proving the selectivity of the suggested methodology. The results showed satisfactory recoveries (99.7 - 100.7%), as shown in Table 4. Accuracy obtained using this method were higher than previously published works [5-7, 9-12, 15-17]. Fig. (3) shows two chromatograms corresponding to paroxetine in pharmaceutical preparations.

4. CONCLUSIONS

The results obtained from the above study indicates that the HPLC procedure developed herein could easily be used for the determination of paroxetine in pharmaceutical preparations with an analysis time below 10 min., using 40% acetonitrile and 60% water, buffered at pH 3. The procedure is sensitive enough to monitor paroxetine in clinical samples and pharmaceuticals. The high values of LOD and LOQ make the method more applicable for quality control labs. The method was successfully applied for the analysis of paroxetine in pharmaceutical preparations with good accuracy and precision. The developed method is fast, robust, easy to handle as well as per sample analysis cost is also low. The next step of the research would be to apply this methodology to the analysis of clinical and biological samples.

### Table 3. Robustness Study

<table>
<thead>
<tr>
<th>Chromatographic Parameter</th>
<th>Variation</th>
<th>Retention Time (min)</th>
<th>N</th>
<th>B/A</th>
<th>Peak Area</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetonitrile amount (%) of mobile phase</td>
<td>38-42</td>
<td>7.23 ± 0.15 (2.1%)</td>
<td>2653 ± 5 (0.2%)</td>
<td>1.89 ± 0.13 (6.8%)</td>
<td>2939 ± 10 (0.3%)</td>
</tr>
<tr>
<td>pH</td>
<td>2.8 - 3.2</td>
<td>7.20 ± 0.10 (1.4%)</td>
<td>2650 ± 10 (0.4%)</td>
<td>1.91 ± 0.07 (3.7%)</td>
<td>2931 ± 4 (0.1%)</td>
</tr>
<tr>
<td>Flow rate (mL/min)</td>
<td>0.9 - 1.1</td>
<td>7.2 ± 0.3 (3.5%)</td>
<td>2653 ± 4 (0.2%)</td>
<td>1.94 ± 0.05 (2.3%)</td>
<td>2928 ± 5 (0.2%)</td>
</tr>
<tr>
<td>Applied voltage (V)</td>
<td>0.88 - 0.92 V</td>
<td>7.17 ± 0.06 (0.8%)</td>
<td>2653 ± 5 (0.2%)</td>
<td>1.94 ± 0.04 (2.1%)</td>
<td>2870 ± 210 (7.3%)</td>
</tr>
</tbody>
</table>

(n = 6).
Table 4. Absolute Recovery of Paroxetine in Various Pharmaceutical Preparations

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Commercially Procured Pharmaceutical Preparation</th>
<th>Found (µg/ml) Mean±S.D.</th>
<th>Absolute Recoveries (% Mean)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Depox</td>
<td>9.6±1.9</td>
<td>100.5%</td>
</tr>
<tr>
<td>2.</td>
<td>Pari-CR</td>
<td>9.5±1.3</td>
<td>99.7%</td>
</tr>
<tr>
<td>3.</td>
<td>Parotin</td>
<td>9.5±1.6</td>
<td>99.8%</td>
</tr>
<tr>
<td>4.</td>
<td>Pxeep</td>
<td>9.6±1.7</td>
<td>100.4%</td>
</tr>
<tr>
<td>5.</td>
<td>Raxit</td>
<td>9.6±1.6</td>
<td>100.7%</td>
</tr>
</tbody>
</table>

samples, as serum, plasma and urine; and the analysis of paroxetine derivatives.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflicts of interest.

ACKNOWLEDGEMENTS

Nitasha Agrawal thanks University Grants Commission, (M.H.R.D. and Government of India) for providing with Junior Research Fellowship.

REFERENCES


Received: September 26, 2012
Revised: November 6, 2012
Accepted: November 7, 2012

© Agrawal et al.; Licensee Bentham Open.
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.